Posts tagged Genetics
With a background in computer programming and an undergraduate degree in molecular genetics, its interesting to see the comparisons at multiple levels – and it looks fairly accurate to me at quick glance. There are some other interesting things that could be covered such as methylation patterns and supercoiled DNA (from a genetics point of view), but hopefully the author will keep updating his page — check it out:
DNA seen through the eyes of a coder.
A recent article at Sciencedaily called Bioengineers Devise ‘Dimmer Swith’ To Regulate Gene Expression In Mammal Cells discusses new technology being developed that combined a targeted DNA repressor protein, and a custom-designed RNAi strand. The repressor is thought to prevent most transcription, but in the event not all genes are repressed, the RNAi is thought to hunt out those transcripts, and destroy them.
Another chemical called Isopropyl-â-thiogalactopyranoside acts as a “dimmer” that can block the repressor protein. Thus by altering the amount of this chemical, repressor and RNAi, they can regulate a gene’s expression. Cool.
The largest study ever conducted on genes and disease turned up 10 new genes that may predispose someone to 7 of the most highly acclaimed disease conditions. Diseases include type 1 and type 2 diabetes, coronary artery disease, hypertension, Crohn’s disease, rheumatoid arthritis, and bipolar disorder. More at: Biggest ever haul of genes linked to diseases.
A company called EnGeneIC in Sydney, Australia have created a targeted drug delivery platform based on “mini bacteria”, or as they call it, EnGeneIC Delivery Vehicles (EDVs). These vehicles look and behave like bacteria, including cell division — albeit, without chromosomes. I may need to dig a little deeper into the science of this one!
In any case, these EDVs have been shown to target tumorigenic tissue, being fed by blood vessels; 30% of an IV dosage reached the cancerous region within 2 hours. It has so far been proven safe in dogs with advanced non-Hodgkin’s lymphoma, as well as in pigs and monkeys.
The study also suggests that these EDVs can carry RNAi or siRNA-based products to their destination, as delivery of these nucleic acids has been proven difficult due to nuclease/enzymatic degredation before reaching its target.